Affiliation:
1. Department of Orthopaedic Surgery, Division of Orthopaedic Oncology, Massachusetts General Hospital Harvard Medical School Boston Massachusetts USA
2. Department of Orthopaedic Surgery, Montefiore Medical Center Albert Einstein College of Medicine New York New York USA
Abstract
AbstractBackgroundVacuum‐assisted closure (VAC) temporization is a technique associated with high local control rates used in myxofibrosarcoma. We sought to compare the costs and postoperative outcomes of VAC temporization and single‐stage (SS) excision/reconstruction.MethodsWe conducted a retrospective analysis of patients with myxofibrosarcoma surgically treated at our institution between 2000 and 2022. Variables of interest included total, direct, and indirect costs for initial episode of care, 90 days and 1 year after initial admission, and postoperative outcomes. Costs were compared between the VAC temporization and SS groups.ResultsAfter matching, 13 patients in the SS group and 23 in the VAC group were analyzed. We found no difference in median and mean total inpatient costs, between the VAC temporization and SS group. While total 90‐day and 1‐year costs were higher in the VAC group compared to the SS group, mean costs were similar. There were no differences in postoperative complications between groups. A subanalysis of the entire cohort (n = 139) revealed lower local recurrence and overall death rates in the VAC temporization group.ConclusionVAC temporization had similar inpatient costs and postoperative outcomes to SS excision/reconstruction. While median 90‐day and 1‐year costs were higher in the VAC group, mean costs did not differ.